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Abstract
PURPOSE—Both prostate cancer and benign prostatic hyperplasia are associated with 
inflammatory microenvironments. Inflammation is damaging to tissues, but it is unclear how the 
inflammatory microenvironment protects specialized epithelial cells that function to proliferate 
and repair the tissue. The objective of this study is to characterize the cell death and cell survival 
response of the prostatic epithelium in response to inflammation.
METHODS—We assessed induction of cell death (TNF, TRAIL, TWEAK, FasL) and cell 
survival factors (IGFs, hedgehogs, IL–6, FGFs, and TGFs) in inflamed and control mouse 
prostates by ELISA. Cell death mechanisms were determined by immunoblotting and 
immunofluorescence for cleavage of caspases and TUNEL. Survival pathway activation was 
assessed by immunoblotting and immunofluorescence for Mcl–1, Bcl–2, Bcl–XL, and survivin. 
Autophagy was determined by immunoblotting and immunofluorescence for free and membrane 
associated light chain 3 (LC–3).
RESULTS—Cleavage of all four caspases was significantly increased during the first 2 days of 
inflammation, and survival protein expression was substantially increased subsequently, 
maximizing at 3 days. By 5 days of inflammation, 50% of prostatic epithelial cells expressed 
survivin. Autophagy was also evident during the recovery phase (3 days). Finally, 
immunofluorescent staining of human specimens indicates strong activation of survival proteins 
juxtaposed to inflammation in inflamed prostate specimens.
CONCLUSIONS—The prostate responds to deleterious inflammation with induction of cell 
survival mechanisms, most notably survivin and autophagy, demonstrating a coordinated induction 
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of survival factors that protects and expands a specialized set of prostatic epithelial cells as part of 
the repair and recovery process during inflammation.
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INTRODUCTION
Continual and recalcitrant inflammation is an extremely common condition in the human 
prostate and has been found to be associated with a number of prostatic diseases including 
prostate cancer and benign prostatic hyperplasia (BPH) [1–4]. Prostatic inflammation is 
characterized by the presence of inflammatory cells in the stroma, epithelium, and lumen of 
prostatic glands where the infiltrate is primarily lymphocytic with secondary accompanying 
macrophages juxtaposed to loci of reactive hyperplasia [1]. The origins of inflammation in 
the prostate remain a subject of debate and are most likely multi-factorial [5]. A role for a 
bacterial component in prostatic inflammation is controversial but is certainly plausible [6–
9], and colonization by non-culturable organisms has been suggested by PCR assays of 
bacterial 16S ribosomal RNA in prostate biopsies as this has been associated with 
histological evidence of inflammation [10]. Numerous nonbacterial causes of inflammation 
have been investigated including viruses, environmental components, systemic hormones, 
and urinary reflux. Whatever the cause, inflammation in the prostate is of considerable 
importance to urological research due to the prevalence and impacts of BPH and prostate 
cancer.
While much has been described regarding prostate disease resulting from oxygen and 
nitrogen radicals during inflammation, proliferative mechanisms associated with repair and 
regeneration are less understood. Repair and regrowth are co-regulated processes 
characteristic of many cellular responses to trauma and in order for tissue recovery to 
proceed, inflammation must orchestrate precise series of events directing damaged cells to 
die, inducing proliferation of protected tissue progenitors to repopulate damaged tissue, and 
promoting differentiation of those expanded cells into proper cell subtypes [11]. Errors in 
these processes allow for expansion of damaged cells in an environment saturated in growth 
promoting factors leading to hyperplasia and desmoplasia [12]. While there is an extensive 
literature in prostate cancer cells regarding survival and cell death escape, mechanisms of 
how inflammation directs cells to avoid death and proliferate are poorly understood.
In addition to the classically understood mechanisms by which cells survive noxious tissue 
conditions—inhibition of pro-apoptotic proteins, induction of pro-survival proteins, and the 
subsequent inactivation of caspases—autophagy represents a process that can be associated 
with both the promotion of apoptosis and the promotion of cell survival and proliferation. 
Autophagy consists of autophagosome formation and effective macromolecule degradation 
[13]. The mechanisms of autophagy are diverse and depend on the origin of the stimulus. 
Autophagy is implicated in a number of diseases including cancer [14]. The removal of 
damaged organelles or proteins can be advantageous for a cell and may act as an escape 
mechanism from cell death [15].
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It is not known how specialized cells in the prostatic epithelium are programmed to avoid 
cell death mechanisms in the noxious condition of inflammation and survive in order to 
repopulate the tissue as part of the innate repair and recovery process. In this study, we 
characterize the immediate induction of cell death mechanisms in our mouse model of 
prostatic inflammation that has been shown to transition from acute to chronic phases of 
inflammation similar to human prostates. Cell death signaling induction is followed by a 
coordinated induction of survival mechanisms that begin in basal epithelial cells and expand 
to include all layers of the epithelium. We also found that autophagy is induced during the 
recovery phases of inflammation. Finally, we found that the most consistently induced of the 
survival proteins, survivin, is associated with inflammation in human prostate specimens, 
and that survivin expression is more tightly correlated with inflammation than with disease 
state of the prostate.
METHODS
In Vivo Induction of Inflammation
All animal experiments were conducted under the approval and supervision of the Indiana 
University School of Medicine Animal Care and Use Committee, and in accordance of 
National Institutes of Health guidelines for animal research. Escherichia coli strain 1677 (2 
× 106/ml, 100 μl per mouse) was instilled through catheters into the urinary tract of 
C57BL/6J wild-type mice, as previously described [5,6,16]. Mice were then inoculated with 
100 μl of BrdU (3.1 mg/ml Roche) for 2 hr before being sacrificed daily for 7 days after 
instillation, and their prostates were removed and separated by lobe (Ventral Prostate [VP], 
Coagulating Gland [CG], and Dorsolateral Prostate [DLP]) for molecular or histological 
analysis. PBS (Phosphate-buffered saline)-instilled animals were used as controls. Tissues 
were either paraffin-embedded for immunohistochemistical analysis or snap-frozen for 
molecular analysis. The E. coli strain 1667 in these experiments is being utilized as a tool 
for the induction of inflammation in the rodent prostate and has been shown to induce 
cellular effects that parallel that of inflammation found in a number of human prostatic 
diseases. In this model, the inflammatory response to bacterial inoculation is characterized 
by a primarily neutrophilic infiltrate in the first and second day that progresses to a primarily 
lymphocytic infiltrate 3–5 days post-inoculation. Macrophages are prevalent to a lesser 
degree throughout both acute and chronic stages. The chronic stage (days 3–5) has a very 
similar leukocytic content and distribution as that found in chronic human prostatic 
inflammation in benign or cancerous prostates [17,18]. The dorsolateral lobe of the rodent 
prostate has been demonstrated to produce the most dynamic and consistent response to 
induction of inflammation [6], and upon verification of this via tissue damage assessment, 
we therefore used this lobe for the molecular analysis of this study. For all experiments this 
model is used for (protein, histology, IF, etc.), dorsal-lateral prostates from six separate mice 
are used as separate data points.
Protein Localization Via Immunohistochemistry
Prostate lobes were fixed in 10% formalin overnight, processed routinely, embedded in 
paraffin, and serially sectioned at 5 μm with a microtome. Tissues were subjected to heat-
induced antigen retrieval in 10 mM citrate buffer (citrate buffer stock solution of 
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monohydrate-free acid citric acid, sodium citrate dehydrate, pH 6.0) for 10 min. Sections 
were blocked at room temperature with a bovine serum albumin (BSA)-serum mixture for 2 
hr and incubated with primary antibody overnight at 4°C. Primary antibodies and dilutions 
included BrdU labeling Detection kit II (1:20, Roche), rabbit anti-Cleaved Caspase 3 (1: 
400, Cell Signaling Technologies, Danvers, MA), rabbit anti-Cleaved Caspase 7 (1:400, Cell 
Signaling Technologies), rabbit anti-Cleaved Caspase 9 (1:400, Cell Signaling 
Technologies), rabbit anti-survivin (1:100, Cell Signaling Technologies), rabbit anti-LC3 
(1:200, Cell Signaling Technologies), and mouse CD45 (1:100, Cell Signaling 
Technologies). Sections were washed with PBS (Phosphate-buffered saline)-Tween and 
incubated with IgG Alexa 488 and IgG Alexa 594-conjugated secondary antibody against 
rabbit or mouse for 1 hr at room temperature (1:100, Invitrogen), followed by 10 min 
incubation with Hoechst 33258 nuclear stain (1 μg/ml). Tissues were washed and covered 
with an aqueous medium and glass coverslips. The sections were analyzed by 
immunofluorescence and the number of positive- and negative-stained cells was determined.
Protein Quantification Via Immunoblotting
Prostate tissues were homogenized in lysis buffer containing protease inhibitor (150 mM 
NaCl, 10 mM tris, 1 mM EDTA, 1 mM benzenesulfonyl fluoride, and 10 μg/ml each of 
aprotinin, bestatin, L-luecine, and pepstatin A) and 1% Triton X-100. The homogenate was 
centrifuged for 20 min at 14,100g at 4 °C and the supernatant was collected and total protein 
concentration was determined by BCA (bicinchoninic acid) assay (Pierce, Rockford, IL). A 
total of 20 μg/well of Protein were resolved by electrophoresis in 4–15% gradient 
polyacrylamide gels. Proteins were transferred to polyvinylidene difluoride membranes, 
blocked for 24 hr [(10% Dry milk, 5% BSA, 0.05% NaN3) in 1xPBS(2.7 mM KCl, 1.5 mM 
KH2PO4, 136 mM NaCl, 8 mM Na2HPO4)-Tween 20] and incubated overnight with one of 
the following primary antibodies: mouse β-actin (1:1000, Cell Signaling Technologies), 
rabbit survivin (1:1000, Cell Signaling Technologies), rabbit Bcl-2 (1:1000, Cell Signaling 
Technologies), rabbit Mcl-1 (1:500, Cell Signaling Technologies), and rabbit LC3 (1:1000, 
Cell Signaling Technologies). After blots were washed six times with PBS-Tween, blots 
were incubated with donkey antibody against rabbit immunoglobulin G conjugated to 
horseradish peroxidase for 1 hr (1:200,000 dilution, Pierce) in nonfat dry milk, PBS, and 
0.05% Tween 20. Peroxidase activity was detected via West Femto chemiluminescence 
reagent (Pierce). Photo images were analyzed by densitometry.
Cell Death/Survival Factors Expression Via ELISA
Prostate tissues were harvested and homogenized from 8-week-old C57BL/6J WT mice 0–
14 days after uropathogenic E. coli strain 1677 instillation. For release experiments, tissues 
were equilibrated for 1 hr in aerated Krebs physiological salt solution, with buffer changes 
of 15 min and then 30 min. Krebs was collected after the experiment and frozen as the 
“released fraction.” Additional tissues were harvested for the total tissue content, and these 
tissues were snap frozen in liquid nitrogen, placed in sterile PBS, and homogenized. Tissue 
slurries were centrifuged at 14,000g for 10 min and the supernatant was collected as the total 
tissue content fraction. All collections were analyzed by ELISA for TNF, TWEAK, TRAIL, 
FAS-Ligand, Shh, IGF-α, IL-1β, IL-6, TGF-β1, and TGF-β3 as recommended by the 
manufacturer (Biosource; Camarillo, CA). Absorbance readings for each concentration were 
McIlwain et al. Page 4
Prostate. Author manuscript; available in PMC 2019 November 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
normalized as a ratio to control non-inflamed prostates. Comparisons between inflammatory 
time points are expressed as mean ±s.e.m. *P <0.05 versus PBS-instilled prostate; using 
analysis of variance (ANOVA).
DNA Fragmentation Via TUNEL
Prostate lobes were fixed in 10% formalin overnight, processed and embedded in paraffin 
and serially sectioned at 5 μm with a microtome and rehydrated as previously mentioned. 
Tissue sections were incubated with Proteinase K working solution (10 μg/ml in 10 nM Tris/
HCl, pH 7.4–8) at RT for 15 min and then rinsed twice with PBS. Fifty micro-litre of 
TUNEL reaction mixture (In Situ Cell Death Detection Kit Fluorescein, Roche Applied 
Science) were added to each section and slides were placed in a humidified atmosphere for 
60 min at 37°C in the dark. The slides were then rinsed three times with PBS and stained 
with Hoechst 33,258 as previously described. Tissues were then washed and covered with an 
aqueous medium and glass coverslips. Samples were directly analyzed under a fluorescence 
microscope using an excitation wavelength in the range of 450–500 nm and detection in the 
range of 515–565 nm (green).
Human Specimens
Human specimens were obtained with appropriate minimal risk institutional review board 
approval according to the approval and guidelines at Indiana University School of Medicine. 
Sections were cut from pre-existing paraffin-embedded human prostate tissues obtained as 
part of a transurethral resection of the prostate (TURP), a prostatectomy, or from prostate 
specimens removed collaterally from bladder cancer patients undergoing radical cystectomy 
(cystoprostatectomy) as control human specimens. These controls were age-matched to the 
BPH-TURP and prostate cancer specimens, and were verified by record to be naïve for 
infection or pretreatment with Bacillus Calmette-Guérin as first-line therapy because these 
patients had presented with muscle invasive bladder cancer. Further, the controls were not 
exhibiting benign prostatic hyperplasia symptoms and were verified by pathology to be 
prostate cancer free. Control regions from both the transition zone and peripheral zone were 
used for analysis as controls for both BPH and prostate cancer, respectively. There were 
prostates collected from 12 separate patients used for this study. For calculation, five random 
20× views were analyzed for survivin and CD45 positive cells and averaged for each 
separate data point.
The age range of specimens is 45–72, with the average age of 64 for BPH specimens, 66 for 
control prostates, and 68 for prostate cancer specimens. Prostate cancer specimens were all 
Gleason 3+3, 3 +4, or 4 +3. All human specimens were stained with survivin and CD45 
antibodies for immunofluorescence, as described above.
RESULTS
Inflammation Causes Tissue Damage and Hyperplasia in a Model of Prostatic Inflammation
Mice instilled with uropathogenic E. coli 1677 exhibited widespread inflammation with 
varying degrees of hyperplasia and dysplasia consistent with previous papers on this model, 
and as has been previously published, the dorsolateral lobe of the prostate produced the most 
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consistent and dynamic response to inflammation [6,16]. Three days after instillation, WT 
animal epithelium develops distinct multilayers and display extensive inflammatory infiltrate 
(Fig. 1). Previous reports from this model indicate that the inflammatory infiltrate in this 
model is primarily neutrophilic 1–2 days post induction, and lymphocytic 3–5 days after 
inflammation with accompanying macrophages [6,16]. This phase mimics what is observed 
in human prostates with chronic inflammation [17,18]. Intense loci of inflammation are 
juxtaposed to epithelial hyperplasia and the prostatic glands juxtaposed to intense 
inflammation show tremendously increased epithelial cell proliferation and hyperplasia. 
Mice exhibiting 1–3 days of inflammation exhibit numerous damaged and apoptotic cells as 
evidenced by pyknotic nuclei and retracted cytoplasm (Fig. 1). These data demonstrate that 
our model of prostatic inflammation is associated with the damaging effects of inflammation 
and cellular damage.
Inflammation Causes Rapid Apoptotic Response
To characterize inflammation-induced apoptosis, we assessed control and inflamed mouse 
prostates for expression of executioner caspase 3, 7, and 6 cleavage via 
immunohistochemistry (Fig. 2A and B). We found an increase in cells exhibiting activation 
(cleavage) of all three executioner caspases with caspase 3 being the most dramatic, peaking 
at day 2 with 1.3% of cells expressing cleaved caspase 3 (n =6 mice). Cleaved caspase 3 
positive cells were primarily found in select basal and luminal epithelial cells of prostatic 
glands and absent from the fibromuscular stroma. In addition, we assessed these tissues for 
later stage apoptosis by staining for nick-end labeling of fragmented DNA. To determine 
this, a terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) was 
performed to measure percent of epithelial cells in later stage apoptosis as described in 
histologic sections of prostate tissue and positive cells were detected by fluorescent 
microscopy (Fig. 2C). Few fluorescein-positive cells were found in days 0 and 1 of infection 
but a significant increase in apoptotic cells was found in day 2 with subsequent decrease by 
day 4. The fluorescein positive cells, like the caspase 3 positive cells, were primarily found 
in the basal and luminal compartments of the prostatic glands.
Inflammation Induces Death and Survival Factor Production and Release
Inflammation induces coordinated and temporal expression and release of known cell death 
factors, subsequently followed by an induction of a panel of known cell survival-inducing 
factors. As measured by ELISA, bona fide cell death-inducing mediators TNFα, TWEAK, 
TRAIL, and FAS ligand are all induced rapidly and transiently upon induction of acute 
inflammation in the dorsolateral prostate, maximizing at 1–2 days after induction (Fig. 3A 
and B). Subsequent to induction of death ligands, the production of known cell survival 
factors Shh, IGF-1, IL-1α, IL-6, TGFβ1, and TGFβ2 are substantially induced in the second 
day of inflammation, and maximizes at day 3 (Fig. 3C and D, n =6 mice). IL-1α, IL-6, and 
TGFβ1 remained significantly induced for 5 days after inflammation induction. These data 
demonstrate that death factors coincide with the acute and neutrophilic phase of 
inflammation, and are coordinately followed by the induction of survival factors 
corresponding to the lymphocytic phase of inflammation.
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Inflammation Induces Cell Survival Signaling Pathways in Response to Apoptotic Signals
We assessed the induction of four previously identified survival signaling molecules, 
previously known to regulate cell survival in prostate cells: survivin, Bcl-2, Bcl-XL, and 
Mcl-1 (Fig. 4). Our data indicate that inflammation induces the expression of survivin, Bcl-2 
and Mcl-1, but had no effect on Bcl-XL expression (Not shown). The most prominently 
induced survival protein by inflammation was survivin, exhibiting an eightfold induction at 
days 3 and 4 after inflammation relative to uninflamed control prostates (Fig. 4A and B; n 
=6 mice). Since survivin was the most dynamic and consistently induced survival factor in 
inflamed prostates, we sought to further characterize its induction. Survivin is rarely 
expressed in control prostates, being expressed in 1% of epithelial cells, and primarily in 
select basal cells (Fig. 4C-top). Immunofluorescence of survivin expression increased 
linearly by day throughout the first 5 days of inflammation (Fig. 4D), and by 5 days 50% of 
the epithelial cells of inflamed prostates were positive for survivin (Fig. 4D), image depicted 
in Figure 4C-bottom. The percentage of survivin-positive cells remained increased for 7 
days of infection. These data indicate that survival proteins are induced during prostatic 
inflammation, corresponding to induced survival factor signals and the lymphocytic phase of 
inflammation, and temporally following the neutrophilic death factor/apoptotic phase.
Inflammation Induces Autophagy: LC 3 Association With the Autophagosome
As autophagy is a cell mechanism that can lead to either cell survival or cell death, we 
sought to characterize its induction in prostatic inflammation. Inflammation increases both 
the expression and vesicle association of the autophagy LC3 (Fig. 5). LC3 is expressed in 
the cytosol of cells and, upon initiation of autophagy, LC3 associates with vesicular 
membranes to form the autophagosome. This causes LC3 to run faster on gels, so a lower 
running band in immunoblotting is indicative of autophagosome-associated LC3, and 
therefore autophagy induction. Immunoblotting of proteins from inflamed prostates 
demonstrates that autophagy is induced by inflammation in the prostate, maximizing at 3 
days of inflammation (Fig. 5A and B; n =6 mice). Additionally, LC3 expression itself is also 
induced after three days of inflammation. To further characterize LC3 during prostatic 
inflammation, we assessed tissue localization by in immunofluorescence. Autophagosome-
associated LC3 is associated with a punctate appearance as the protein is concentrated 
around the vesicle (Fig. 5C). We found that the number of prostatic epithelial cells 
exhibiting punctate LC3 increased from 4% of epithelial cells to 25% by the third day of 
inflammation (Fig. 5D). Autophagic cells were found throughout the epithelium, in both 
luminal and basal layers. These data demonstrate that the potentially cell survival 
mechanism of autophagy is induced by acute prostatic inflammation, and maximizes during 
the lymphocytic phase.
Survivin Is Induced Juxtaposed to Inflammation in Human Prostate Specimens
In our in vivo mouse model of prostatic inflammation, survivin is the most consistently 
induced survival factor in the prostate in response to inflammatory signals. Because of this, 
we sought to determine if it is induced by inflammation in human prostate specimens. To 
address inflammation and survival protein expression in human tissue, we co-stained for 
CD45+ (immune cells) and survivin in non-diseased (prostates removed from cystectomies), 
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BPH specimens (via TURP), and prostate cancer specimens (removed via prostatectomy), 
12 tissues (from 12 separate patients) per group. As previously reported, survivin is induced 
in the majority of prostate cancer specimens, and is not expressed in the majority of non-
diseased control prostates. However, our staining also demonstrated that regions of 
inflammation associated with survivin induction regardless of whether the region was found 
in non-diseased or diseased prostates (Fig. 6). We defined both inflamed and non-inflamed 
regions in all three prostatic conditions (non-diseased, BPH, and cancer) by the number of 
CD45-evident 20× fields. Based on our previously established mouse model inflammatory 
scoring [6], we set the criteria for inflammation to be greater than or equal to 30 CD45+ cells 
per 20× field, and non-inflamed regions were defined as less than 10 CD45+ cells per field. 
Using this criteria, we quantified the number of survivin-positive cells in sections from 
inflamed and non-inflamed regions in non-diseased, BPH, and cancerous prostate 
specimens. We found that regardless of condition, inflamed fields were associated with 60–
70% of epithelial cells positive for survivin, while non-inflamed non-diseased and BPH 
fields exhibited less than 10% of epithelial cells positive for survivin, and non-inflamed 
cancerous fields were associated with 24% positive cells (Fig. 6B). While there was a 
threefold increase in survivin-positivity among prostate cancer specimens independent of 
inflammation, the primary difference between diseased and non-diseased prostates was the 
prevalence of inflammation (Fig. 6C). In non-diseased prostates, severe inflammation 
represented on average 11% of sections, while in BPH and prostate cancer sections severe 
inflammation constituted 82% and 71% of the section, respectively. There was no difference 
in the severity of inflammation in the 20× views quantified in this study once they were 
determined to be in the “severe” (>30 CD45-positive leukocytes per field) category. 
Additionally, we observed no significant difference in survivin-positivity between the 
transition zone and peripheral zone of non-diseased prostates.
DISCUSSION
Inflammation is a common feature of prostate biology and is believed to be associated with 
the disease progression involved in both BPH and prostate cancer. Yet, inflammation is also 
a destructive process that involves a repair and recovery stage in which protected cells must 
survive the initial insults of inflammation, followed by their rapid proliferation as a means to 
repopulate the damaged tissue. The cell signaling mechanisms involved in coordinating 
these events is not understood, and little is known as to how the epithelium of tubular 
structures such as the prostate protects the specialized cells that are the keystones of 
epithelial repair and recovery.
The data in the present study indicate that inflammation induces a profile of cell death and 
cell survival-inducing factors, coordinated such that death factors and induction of cell death 
cellular mechanisms occurs within the first 48 hr after induction of inflammation, followed 
by a maximized expression of survival factors and signaling pathways. Inflammation causes 
visible death of the prostatic epithelium in the first 48 hr of inflammation as evidenced by 
H&E staining and confirmed by activation of caspases and nick-end labeling. Coordinate 
with this, there is a significant induction of cell death factors including TNFα, TWEAK, 
TRAIL, and FasL. Secondary to cell death, the acute inflammation time course exhibits 
induction of known survival factors including growth factors, cytokines, and developmental 
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morphogens that correspond to activation of survival pathways that include survivin, Mcl-1, 
and Bcl-2. We conclude from this that a population of epithelial cells resides in the prostatic 
epithelium that responds to inflammatory signals by inducing survival factors, and functions 
to repopulate the tissue during repair secondary to the damaging effects of inflammatory 
triggers.
Additionally, autophagy mechanisms maximize during this survival phase and may represent 
an additional cell survival mechanism in prostatic epithelial cells. Autophagy is indicated by 
the formation of autophagosomes for cell protein digestion during stress. Cells in autophagy 
can either use the digested material for survival, or they can be entered into the apoptotic 
cascade if the stress time period endures. During the induction of autophagy, the normally 
cytosolic protein Light Chain 3 (LC3) associates and participates in the formation of the 
autophagosome. As such, the association of LC3 in a lipid fraction—that of a membrane—
indicates the induction of autophagy. In our study, autophagosome-associated LC3 was 
evident by two methods: the faster-running band at 14 KD in immunoblotting that indicates 
autophagosome association; secondly, the specific exhibition of LC3 into punctate 
formations indicating the presence of autophagosomes. Our data demonstrate a substantial 
increase in the faster running band by immunoblotting, and in the number of epithelial cells 
exhibiting punctate LC3 containing autophagosomes. From this we conclude that 
inflammation induces autophagy in a subset of prostate epithelial cells in experimental 
models of prostatic inflammation.
The mouse model used in this study is a model of acute inflammation that progresses to 
chronic inflammation. This is characterized by an early neutrophilic infiltrate that dominates 
in the first 2 days of induction, and progresses to a primarily lymphocytic and monocytic 
infiltrate in days 3–5. This later lymphocytic chronic stage of the inflammatory response has 
a cellular infiltrate and an expression profile consistent to what is observed in human 
chronically inflamed prostates. The time course of cellular infiltrate in this model exhibits 
remarkably little experimental variation error, demonstrating that the time course of the 
inflammatory response is highly reproducible and consistent. Further, inflammation in this 
model was accompanied by increased expression of several inflammatory mediators and 
gene products including IL-1 family members, IL-6, COX-2, IGF-1, and FGFs, commonly 
observed in chronic prostatic inflammation. Therefore it is not unexpected that an increase in 
survival protein expression occurs during the chronic phase of this model, just as is observed 
in human chronically inflamed prostates.
Survivin was the most consistent and substantially induced of the survival proteins in our 
mouse study, and we sought to validate its responsiveness to inflammation in human 
specimens. While the expression of survivin is well-known to be induced in both BPH and 
prostate cancer [19–21], this is the first report we are aware of in which survivin localization 
is characterized juxtaposed to inflammation. We found that survivin expression does localize 
to areas of severe inflammation, but what was striking is how this localization is largely 
disease-independent. There was no difference in the number of survivin-positive cells in 
inflamed regions between BPH, cancer, and non-diseased regions; the primary 
discriminating factor between the pathological states is how widespread inflammation is in 
each state. Severe inflammation was present in over 80% of our BPH sections and over 70% 
McIlwain et al. Page 9
Prostate. Author manuscript; available in PMC 2019 November 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
of our prostate cancer specimens, but was only a feature in less than 15% of non-diseased 
sections. Inflammation was associated with reactive hyperplasia and stromal desmoplasia in 
all tissues where it was present, but there was no consistent formation of any pre-malignant 
epithelial lesions such as dysplasia in inflamed regions of non-diseased prostates. We 
propose that the previously published findings describing high survivin localization in 
diseased prostates is in large part a factor of the increased inflammation in those specimens. 
It must be noted, however, that in those uncommon regions of prostate cancer that are not 
associated with inflammatory infiltrate, there is still an increased number of survivin-
positive cells, independent of inflammation. Therefore we conclude that prostate cancer does 
have intrinsic survivin induction relative to benign epithelium, but this is still enhanced with 
inflammation. BPH specimens did not exhibit any increase, absent of inflammation.
There is a clear association of BPH with inflammation, both in proliferating cells and in 
association with symptoms. The prevalence of inflammation in BPH specimens is repeatedly 
reported to be found in between 75% and 100% of specimens. A well-characterized study by 
Nickel et al. reported substantial prostatic inflammation in 100% of 80 men undergoing 
prostatectomy for treatment of BPH [22], and histological examination of prostates from 
8224 men enrolled in the REDUCE trial revealed inflammation in 78% of specimens [23]. 
Critically, histologically verified inflammation is the most tightly correlated histological 
finding to prostate symptomology in men with BPH [24]. Similarly, strong evidence links 
inflammation to the development, growth, and survival of cancer in the prostate [1]. 
Histopathology studies of human prostatectomy specimens identified lesions characterized 
by proliferating epithelial cells and activated inflammatory cells (proliferative inflammatory 
atrophy, PIA) in juxtaposition to areas of neoplasia. Sustained cell proliferation in the 
inflammatory environment rich in growth factors, activated stroma, and DNA-damage-
promoting agents, could potentiate, and/or promote neoplasia. Additionally, proliferative 
inflammatory atrophy (PIA) is characterized by proliferating epithelial cells and is found in 
association with prostatic intra-epithelial neoplasia (PIN) and prostate cancer. These findings 
have prompted the hypothesis that chronic inflammation is involved in the genesis and/or 
progression of prostate cancer.
Several aberrant molecular mechanisms in apoptosis pathways have been identified to result 
in prostate disease, and androgen axis modulators—a mainstay of our therapies against 
prostate cancer growth—rely heavily on induction of apoptotic mechanisms for their 
efficacy [25–28]. Multiple modifications to cell death and survival pathways have been 
discovered in prostate tumors, BPH, and prostate cell lines that may participate in either 
tumorigenesis, proliferation, or therapy resistance. Increased expression of the survival 
proteins survivin, Bcl-2, Bcl-xL, Bcl-ω, and Mcl-1 are associated with prostate cancer and 
BPH, and interestingly inhibiting their expression sensitizes cells to cytotoxic therapies [29–
31]. In addition, down-regulation or inhibition of these survival proteins results in increased 
chemosensitivity in prostate cell lines [31–33]. Finally, prostate cancer cells exhibit 
decreased death receptor expression and upregulated decoy death receptor expression, and 
this results in diminished apoptosis induction capacity [34,35]. Our present findings add to 
the understanding of the balance between pro-apoptotic and pro-survival signaling in 
prostate epithelial cells by demonstrating extrinsic control of both death factors and 
subsequent survival factor induction in a specialized cell population, by inflammation.
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CONCLUSION
Our data indicate that prostatic tissue responds to the damaging effects of inflammation by 
an active induction of cell survival factors and signaling mechanisms, most notably survivin. 
Autophagy, a potential cell survival mechanism, is also substantially activated and these 
survivin-expanded cells may depend upon survival signaling. This study further suggests 
that there is a coordinated induction of survival factors that function to protect and expand a 
specialized set of prostatic epithelial cells. In human prostate, induction of survivin is 
juxtaposed to loci of severe inflammation induction in benign and cancerous prostates, and 
inflammation appears to be more acutely the inducer of this critical protein in the 
microenvironment than cancer itself is. Future studies will be aimed at determining if early 
stage prostate cancer set in inflammatory microenvironments survive the damaging effects of 
inflammation using these mechanisms.
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Fig. 1. 
Hematoxylin and Eosin staining of 3 day inflamed dorsolateral prostates in the mouse 
prostatic inflammation model. A: (200×) Non-inflamed control prostate shows 
pseudostratified epithelium and very few apoptotic or autophagic cells. B: 200× Inflamed 
prostatic duct shows layering of epithelium characteristic of reactive hyperplasia during 
inflammation, but also shows numerous damaged and apoptotic cells as evidenced by 
pyknotic nuclei and retracted cytoplasm (arrows). C: 400× Image of damaged epithelial cells 
in hyperplastic epithelium in inflamed prostate.
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Fig. 2. 
Inflammation of the mouse prostate results in induced apoptotic signaling. A: Fluorescent 
image (200×) of cleaved caspase 3 (green) in the epithelium (PanCK-red) of mouse prostates 
inflamed 3 days. B: Calculated data of epithelial cells for cleaved caspases 3, 7, and 6 from 6 
mouse dorsal-lateral prostate lobes inflamed to the time points shown, expressed as 
percentage of cleaved caspase-positive cells within the epithelial compartment. C: 
Fluorescent image (200×) of TUNEL-positive cells. D: Calculated data of epithelial cells for 
TUNEL from 6 mouse dorsal-lateral prostate lobes inflamed to the time points shown, 
expressed as percentage of TUNEL-positive cells within the epithelial compartment. All 
data are expressed as mean ±s.e.m. *P <0.05 versus PBS-instilled prostate; comparisons 
using analysis of variance (ANOVA), n =6.
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Fig. 3. 
Inflammation induces the expression and release of known cell death factors, followed by an 
induction of a panel of known cell survival-inducing factors. A: Total tissue content of 
TNFα, TWEAK, TRAIL, and FAS ligand are all induced rapidly upon induction of 
inflammation in the dorsolateral prostate, maximizing at 1–2 days after induction. B: 
Correspondingly, the released fraction of these death ligands increases, indicating that 
release of the factor occurs allowing their function. C: Subsequently, the induction of known 
cell survival factors Shh, IGF-1, IL-1α, IL-6, TGFβ1, and TGFβ2 begins in the second day 
of inflammation, and maximizes at day 3. IL-1α, IL-6, and TGFβ1 remained induced for 5 
days after inflammation induction. D: The released fraction of cell survival factors increases 
correspondingly to their production. All peptides were assessed by ELISA of whole 
dorsolateral prostate lobes and calculated as picogram of peptide per gram of tissue. Data 
were then normalized as a ratio to control non-inflamed prostates at the given time point of 
induction, for presentation. All data are expressed as mean ±s.e.m. *P <0.05 versus PBS-
instilled prostate; comparisons using analysis of variance (ANOVA), n =6. Asterisk-labeled 
time points are those that show significant inducibility of all death or survival factors.
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Fig. 4. 
Inflammation induces three primary cell survival signaling pathways in mouse dorsolateral 
prostates, most prominently, survivin. A: Immunoblot example of induction of survivin, 
Bcl-2, and Mcl-1 during the time course of inflammation in mouse prostates. B: Quantified 
data of relative expression of all three survival proteins during prostatic inflammation; data 
were calculated as ratio of pixel intensity of the given survival protein, relative to β-actin, 
and expressed as ratio of expression to control prostates at the corresponding time of 
induction. Data are expressed as mean ±s.e.m. *P <0.05 versus PBS-instilled (control) 
prostate; comparisons using analysis of variance (ANOVA), n =6. C: Immunofluorescence 
of survivin expression (green) in 5 day instilled control (top) and inflamed (bottom) 
dorsolateral prostates demonstrating epithelial cell (PanCK, red) expression in the nucleus 
during inflammation. D: Quantified cell counting of epithelial cells positive for survivin 
expression; data expressed are the percentage of epithelial cells expressing survivin in 
control and inflamed prostates at each time point of inflammation. All data are expressed as 
mean ±s.e.m. *P <0.05 versus PBS-instilled prostate; comparisons using analysis of variance 
(ANOVA), n =6.
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Fig. 5. 
Inflammation autophagy marker expression in mouse dorsolateral prostates. A: Immunoblot 
example of induction of the autophagy marker LC3 at inflammation time points indicated; 
the higher running band (cyt) represents cytosolic LC3 while the lower running band (Aph) 
indicates LC3 associated in the autophagasome, and is indicative of autophagy induction. B: 
Quantified data of relative expression of all cytosolic and autophagasome-associated LC3; 
data were calculated as ratio of pixel intensity of the LC3 form, relative to β-actin, and 
expressed as ratio of expression to control prostates at the corresponding time of induction. 
Data are expressed as mean ±s.e.m. *P <0.05 versus PBS-instilled (control) prostate; 
comparisons using analysis of variance (ANOVA), n =6. C: Immunofluorescence of LC3 
(green) localization in 3 day instilled control (top) and inflamed (bottom) dorsolateral 
prostates demonstrating the characteristic punctate LC3 Localization with the 
autophagasome of autophagic epithelial cells, a further indicator of autophagic cells 
(PanCK, red). D: Quantified cell counting of epithelial cells positive for punctate LC3 
Localization; data expressed are the percentage of epithelial cells expressing punctate LC3 
in control and inflamed prostates at each time point of inflammation. All data are expressed 
as mean ±s.e.m. *P <0.05 versus PBS-instilled prostate; comparisons using analysis of 
variance (ANOVA), n =6.
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Fig. 6. 
Human prostate specimens demonstrate intense survivin staining juxtaposed to regions of 
inflammation. A: Immunofluorescent images of non-inflamed or inflamed human prostates 
representing non-diseased controls (peripheral zone) taken from cystoprostatectomy cancer 
and BPH-free prostate specimens, BPH specimens (transition zone from TURP), or prostate 
cancer specimens, as indicated. Sections were stained for survivin (green) and CD45, a pan 
leukocyte marker (red) to identify regions of inflammation. Sections were deemed non-
inflamed if they exhibited less than 10 Leukocytes per 20× field, and inflamed if they 
exhibited greater than 30 Leukocytes per field. B: Quantified cell counting of epithelial cells 
positive for survivin expression in human prostates; data expressed are the percentage of 
epithelial cells expressing survivin in non-inflamed and inflamed prostates at each time point 
of inflammation—three 20× fields per prostate section were averaged for each data point, 
and all data are expressed as mean ±s.e.m. *P <0.05 inflamed versus non-inflamed prostate; 
#P <0.05 disease condition versus non-diseased control. Analysis of variance (ANOVA), n 
=12 human prostates. C: percent of sections from each human prostate group (non-diseased, 
BPH, and cancer) that exhibited 30 Leukocytes per 20× section. Three 20× fields per 
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prostate section were averaged for each data point, and all data are expressed as mean 
±s.e.m. #P <0.05, disease condition versus non-diseased control. Analysis of variance 
(ANOVA), n =12 human prostates.
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